| 000 | 01484 a2200373 4500 | ||
|---|---|---|---|
| 005 | 20250517195403.0 | ||
| 264 | 0 | _c20180309 | |
| 008 | 201803s 0 0 eng d | ||
| 022 | _a1744-7607 | ||
| 024 | 7 |
_a10.1080/17425255.2018.1432594 _2doi |
|
| 040 |
_aNLM _beng _cNLM |
||
| 100 | 1 | _aPatti, Francesco | |
| 245 | 0 | 0 |
_aPharmacokinetic drug evaluation of daclizumab for the treatment of relapsing-remitting multiple sclerosis. _h[electronic resource] |
| 260 |
_bExpert opinion on drug metabolism & toxicology _cMar 2018 |
||
| 300 |
_a341-352 p. _bdigital |
||
| 500 | _aPublication Type: Journal Article; Review | ||
| 650 | 0 | 4 | _aAnimals |
| 650 | 0 | 4 |
_aAntibodies, Monoclonal, Humanized _xadministration & dosage |
| 650 | 0 | 4 | _aBiological Availability |
| 650 | 0 | 4 | _aDaclizumab |
| 650 | 0 | 4 | _aDose-Response Relationship, Drug |
| 650 | 0 | 4 | _aHumans |
| 650 | 0 | 4 |
_aImmunoglobulin G _xadministration & dosage |
| 650 | 0 | 4 |
_aImmunosuppressive Agents _xadministration & dosage |
| 650 | 0 | 4 |
_aInterleukin-2 Receptor alpha Subunit _ximmunology |
| 650 | 0 | 4 | _aMagnetic Resonance Imaging |
| 650 | 0 | 4 | _aMedication Adherence |
| 650 | 0 | 4 |
_aMultiple Sclerosis, Relapsing-Remitting _xdrug therapy |
| 700 | 1 | _aChisari, Clara G | |
| 700 | 1 | _aD'Amico, Emanuele | |
| 700 | 1 | _aZappia, Mario | |
| 773 | 0 |
_tExpert opinion on drug metabolism & toxicology _gvol. 14 _gno. 3 _gp. 341-352 |
|
| 856 | 4 | 0 |
_uhttps://doi.org/10.1080/17425255.2018.1432594 _zAvailable from publisher's website |
| 999 |
_c28008562 _d28008562 |
||